光热疗法介导的混合膜衍生纳米配方用于增强癌症治疗
Xia Cao1,2, Tianwen Deng1,2, Qin Zhu1,2
1Department of Pharmaceutics, School of Pharmacy, Centre for Nano Drug/Gene Delivery and Tissue Engineering, Jiangsu University, Zhenjiang, People's Republic of China.
这项研究开发了混合膜涂层纳米颗粒 (EMHM) 封装埃莫丁和糖素 (EG@EMHM NPs),以增强抗瘤药物输送. 这些纳米颗粒通过光动力学疗法显示出更好的溶解性和强大的抗瘤作用,对黑色素瘤有所改善.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 埃莫丁作为抗瘤药物表现有前途,但溶解性差,限制了其临床应用.
- 开发新的药物输送系统对于克服不溶性天然化合物的药理学限制至关重要.
研究的目的:
- 创建混合膜涂层纳米颗粒 (EG@EMHM NPs) 以改善埃莫丁的输送和增强抗瘤功效.
- 调查用于治疗黑色素瘤的含有emodin的纳米颗粒的联合化疗-光动力学治疗潜力.
主要方法:
- 通过融合红细胞和巨细胞膜来制造混合膜纳米粒子 (EMHM).
- 在EMHM中封装emodin和glycyrrhizin以形成EG@EMHMNP.
- 在黑色素瘤模型中评估颗粒大小,封装效率,细胞毒性,反应性氧物种生成,亡诱导和抗瘤作用.
主要成果:
- EG@EMHM NPs的平均颗粒大小为170 ± 20nm,封装效率高 (98.13 ± 0.67%).
- 与自由埃莫丁相比,EG@EMHM NP的IC50值显著降低,并且在光动力学治疗 (PDT) 下增强了ROS生成.
- 通过调节BAX和BCL-2通路,PDT介导的EG@EMHMNP诱导了亡,并通过调节BAX和BCL-2通路,对黑色素瘤产生了显著的抗瘤作用.
结论:
- EG@EMHM NPs有效地提高了emodin的溶解性和生物可用性,以增强抗瘤活性.
- 使用EG@EMHMNP的联合化疗-PDT为皮肤黑色素瘤提供了一个有希望的向治疗方法.
- 这种方法为提供了提供其他不溶的传统中医成分的潜在策略.
更多相关视频
06:42Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
Published on: May 9, 2025
07:47Custom-designed Laser-based Heating Apparatus for Triggered Release of Cisplatin from Thermosensitive Liposomes with Magnetic Resonance Image Guidance
Published on: December 13, 2015
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
